Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study)
Description
CONCLUSION: The combined fluvoxamine treatment did not add benefit in preventing deterioration in mild-to-moderate COVID-19 patients without the immunomodulatory effect observed, although it demonstrated low hospitalization rates, oxygen supplemental
